Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest, once again. We plan to hang with a short person or two, promenade the spirited official mascot and spend some time in front of the telly. And what about you? This remains a fine time to enjoy the great outdoors. You could stock up on turkey since the holiday is nearing or sound an alarm if you stumble across evidence of election fraud. Perhaps you might reach out to someone feeling isolated. Well, whatever you do, have a grand time. But be safe —wear a mask. Enjoy, and see you soon. …

Pfizer (PFE) and BioNTech (BNTX) plan to apply Friday to the Food and Drug Administration for an emergency use authorization for their Covid-19 vaccine, a watershed moment in the effort to curb the global pandemic, STAT says. It is unclear how long the FDA will take to review the application, though the agency is expected to move swiftly. The FDA pledged to seek advice from an expert panel of outside experts before ruling on the application, and panel members have been asked to hold three days in December as potential meeting dates.


The European Union could pay more than $10 billion to secure hundreds of millions of doses of the Covid-19 vaccines being developed by Pfizer and BioNTech, and CureVac (CVAC), Reuters reports. The EU agreed to pay $18.34 per dose for the vaccine from Pfizer and BioNTech, which is less per dose than the U.S. for an initial supply. The companies are using a tiered pricing formula based on volume and delivery dates. The EU has separately agreed to pay $11.84 per dose for an initial supply of 225 million doses of the CureVac vaccine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!